CSF ctDNA Status Predicts Survival in Leptomeningeal Metastases: Meta-Analysis

This meta-analysis aimed to assess the prognostic value of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) in patients with leptomeningeal metastases (LMD) from solid tumors. The study included 14 studies with a total of 963 patients evaluating baseline CSF ctDNA and two studies with 26 patients assessing longitudinal ctDNA kinetics. The primary endpoint was overall survival (OS), with progression-free survival (PFS) as a secondary endpoint. The analysis found that patients with adverse baseline CSF ctDNA status, such as EGFR mutation positivity, had significantly worse OS (pooled HR 2.40, 95% CI 1.73-3.33) and PFS (pooled HR 2.45, 95% CI 1.36-4.44). Longitudinal studies indicated that increasing CSF ctDNA variant allele fraction was associated with worse OS (pooled HR 4.11, 95% CI 1.25-13.48). The heterogeneity was moderate for OS (I²=36.6%) and low for PFS (I²=15.5%) and longitudinal OS (I²=8.5%). No specific safety or adverse events were reported in relation to CSF ctDNA testing. These findings suggest that baseline and serial CSF ctDNA measurements could serve as valuable biomarkers for survival outcomes in LMD, potentially guiding therapeutic decisions and complementing clinical and radiographic assessments. The study highlights the need for prospective, standardized, multi-timepoint CSF ctDNA studies to further validate these findings and integrate CSF ctDNA monitoring into clinical practice.

What if a simple test could help predict how long someone with advanced cancer might live? For patients dealing with leptomeningeal disease, a severe complication where cancer spreads to the brain and spinal cord, this question is particularly urgent. Treating this condition is tough, and current methods to assess how well treatment is working are limited. In a recent analysis of multiple studies, scientists found that testing cerebrospinal fluid for circulating tumor DNA can give valuable clues about a patient's condition. They discovered that certain DNA markers in the fluid were associated with worse survival outcomes. For example, patients with specific mutations had significantly shorter survival times. This means that by regularly monitoring these DNA levels, doctors could better tailor treatments based on how the disease is progressing. However, while these findings are promising, more research is needed to standardize how this testing is done and to understand its full potential. For patients, this could mean a future where treatments are more personalized and effective, offering hope in a challenging battle against cancer.